CORT
Undervalued by 199.4% based on the discounted cash flow analysis.
Market cap | $7.66 Billion |
---|---|
Enterprise Value | $7.60 Billion |
Dividend Yield | $0 (0%) |
Earnings per Share | $1.35 |
Beta | 0.18 |
Outstanding Shares | 104,106,000 |
Return on Equity | - |
---|---|
Return on Assets | - |
Return on Invested Capital | - |
P/E Ratio | 56.63 |
---|---|
PEG | -210.36 |
Price to Sales | 11.36 |
Price to Book Ratio | 11.36 |
Enterprise Value to Revenue | 11.08 |
Enterprise Value to EBIT | 68.51 |
Enterprise Value to Net Income | 57 |
Total Debt to Enterprise | 0 |
Debt to Equity | 0.03 |
No data
No data
Corcept is a commercial-stage company engaged in the discovery and development of drugs to treat severe metabolic, oncologic and psychiatric disorders by modulating the effects of the hormone cortisol. Korlym® was the first drug approved...